Autologous Cytotoxic T Lymphocyte Targeting Tumor Antigen (CTL)

Autologous cytotoxic T lymphocytes (CTLs) targeting tumor antigens are a population of a patient's own T cells that have been activated and expanded to specifically recognize and kill tumor cells expressing particular antigens. These CTLs are generated by isolating immune cells from the patient, stimulating them with tumor-associated or tumor-specific antigens (often presented by autologous dendritic cells), and expanding the antigen-reactive CTL population ex vivo before reinfusion into the patient. The primary function of these autologous CTLs is to recognize peptide fragments derived from tumor antigens presented on major histocompatibility complex (MHC) class I molecules on the surface of cancer cells. Upon recognition, CTLs engage in direct cytolytic activity against target tumor cells through mechanisms such as perforin/granzyme-mediated apoptosis or Fas/FasL interactions. These responses can be highly specific for mutated or overexpressed proteins unique to cancer cells, minimizing off-target effects.

Other names

Autologous Tumor-Specific T cellsAutologous Antigen-Specific CTLsPersonalized T cell therapyTumor-infiltrating lymphocytes (TILs)Engineered T cells

Autologous cytotoxic T lymphocytes (CTLs) targeting tumor antigens recognize peptide fragments derived from tumor antigens presented on MHC class I molecules on cancer cells. Upon recognition, CTLs engage in direct cytolytic activity against target tumor cells through mechanisms such as perforin/granzyme-mediated apoptosis or Fas/FasL interactions. They also secrete cytokines like IFN-γ that enhance anti-tumor immunity.